Pipeline includes Evoltra (Clofarabine), Modrenal (for which Bioenvision
has obtained regulatory approval for marketing in the United Kingdom"
Financial Snapshot as of 5/24/07
Bioenvision is currently
developing products for hematologic malignancies, solid tumors and
Bioenvision is planning to develop products
for other therapeutic areas as well. In addition, the Company has
in-licensed technologies to reduce the impact of blood-borne and
Bioenvision's product line can be viewed
Bioenvision has teamed up with
Genzyme Corp. to develop clofarabine, a treatment for leukemia in children, the
magazine said. Bioenvision aims to expand its use for elderly patients with
acute myeloid leukemia in Europe, where it has marketing rights.
Steven Rouhandeh, chief executive of
SCO, is quoted by BusinessWeek as saying that when Europe approves clofarabine
for adults, "Bioenvision will rocket," adding that by then, Genzyme
might opt to buy Bioenvision. A decision is expected in 2007.
Soros Fund Management and
Perseus-Soros BioPharma Fund own a combined 12 percent stake in BIVN according
primary focus is
the acquisition, development and marketing of compounds and technologies for
the treatment of cancer. Bioenvision has a broad pipeline of products for
the treatment of cancer, including: Evoltra, Modrenal (for which Bioenvision
has obtained regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to initial
hormone therapy), and other products. Bioenvision is also developing Suvus
which is currently in clinical development for refractory chronic hepatitis
The company also offers various anti-infective technologies,
including the OLIGON technology, an advanced biomaterial that has been
incorporated into various FDA approved medical devices. In addition, it provides an animal health product, Vetoryl, for
the treatment of Cushing's disease in dogs; and Velostan, a cytostatic drug
under investigation as an anticancer agent and as an antimicrobial. The
company sells its products to wholesale distributors and directly to
hospitals, clinics, and retail pharmacies in the United States and the
United Kingdom. It has co-development partnership with Genzyme Corporation.
News and Press Releases
investors flock to tiny Bioenvision -magazine
Reports Third Quarter 2007 Financial Results
Receives $7.4 Million in Warrant Exercises by Perseus-Soros
Biopharmaceutical Fund & SCO Capital
For the latest News and
Quotes on BIVN Click Here.
345 Park Avenue
New York, NY 10154
BIVN filings with the SEC can be found here.
All Fillings are current and the Company is fully reporting.
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
For continuing coverage of BIVN, please sign up for our free newsletter.
Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a
Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out
to be. All materials presented on our web site and individual reports
released to the public through this web site, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative.
This is not to be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to profile involve a
degree of investment risk and volatility. Particularly Small-Caps and OTC-BB
stocks. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the information on our web
site or within our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold
positions in securities mentioned herein, and may make purchases or sales in
such securities featured on our web site or within our reports. In order to
be in full compliance with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview.com web site.
SmallCapReview.com has not been compensated by Bioenvision nor do we
hold any shares at this time. SmallCapReview.com may decide to purchase or sell shares on a voluntary
basis in the open market before, during or after the profiling period of
this report. Information presented on our web site and within our reports
contain "forward looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as “expects’”, “will,” “anticipates,”
“estimates, “believes,” or that by statements indicating certain
actions “may,” “could,” or “might” occur.
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE
INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP
SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its